Owlet, Inc.

NYSE:OWLT

Medical - Devices

Healthcare
$3.67 +9.76%

+$0.46 today

Market cap
$107.24M
Beta
1.86
P/E (TTM)
-0.4
EPS (TTM)
-$12.67
52W Low $4.19High $16.94

Volume 0.64M

Average 0.24M

OWLT Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Owlet, Inc.NYSE: OWLT

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 54.5%

Gross margin was 54.5% in Q1 FY2026, up 0.8 pp from a year earlier. On a trailing-twelve-month basis it was 50.9%, down 1.4 pp year over year. Over 3 fiscal years it widened by 17.0 pp.

Context

  • Gross margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
54.5%+6.9 pp QoQ
Last fiscal yearDec 2025
50.6%+0.3 pp YoY
LTMMar 2026
50.9%-1.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.8 pp——
1 year+0.3 pp——
3 years+17.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
50.6%
Year-over-year change
+0.3pp

Gross Margin vs competitors

How OWLT compares with its peers on the latest reported figures

  • OWLT's LTM Mar 2026 gross margin of 50.9% is the 3rd highest of the 8 companies compared; the peer median is 28.3%.
  • Its year-over-year change of -1.4 pp is the 4th highest of 8, against a peer median of -2.1 pp.
  • Over three fiscal years its change of +17.0 pp compares with a peer median of -7.3 pp.
OWLT Competitors Peer median
Gross Margin for OWLT and competitors
Company Period LTM level YoY 3-year change
MXCTMaxCyte, Inc.LTM Mar 202680.7% -0.2 pp-7.3 pp
ANIKAnika Therapeutics, Inc.LTM Mar 202658.6% -4.1 pp-7.8 pp
OWLTOwlet, Inc.LTM Mar 202650.9% -1.4 pp+17.0 pp
LNSRLENSAR, Inc.LTM Mar 202645.3% -2.1 pp-10.0 pp
AVRAnteris Technologies Global Corp.LTM Mar 202628.3% -24.8 pp-25.9 pp
RPIDRapid Micro Biosystems, Inc.LTM Mar 202612.4% +6.3 pp+72.5 pp
LUCDLucid Diagnostics Inc.LTM Mar 2026-40.0% +27.6 pp+798.4 pp
CRDFCardiff Oncology, Inc.LTM Mar 2026-2105.7% -548.4 pp+0.0 pp
CRBPCorbus Pharmaceuticals Holdings, Inc.FY2025— ——
ELTXElicio Therapeutics, Inc.FY2025— ——
Peer median (excluding OWLT) 28.3%-2.1 pp-7.3 pp

Competitors are the stored peer set for OWLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue75.84M69.2M54.01M78.06M105.71M
Cost of Revenue40.78M45.89M31.42M38.75M52.18M
Gross Profit35.06M23.31M22.59M39.31M53.53M
Gross Margin46.2%33.7%41.8%50.4%50.6%
Research & Development21.43M27.9M10.35M9.8M14.08M
Selling, General & Admin69.42M80.04M40.87M49.73M47.72M
Operating Expenses90.85M107.93M51.22M59.53M61.79M
Depreciation & Amortization1.13M2.67M2.21M1.38M590K
EBITDA(42.71M)(75.53M)(27.49M)(9.47M)(35.64M)
EBITDA Margin-56.3%-109.1%-50.9%-12.1%-33.7%
Operating Income(55.79M)(84.62M)(28.63M)(20.22M)(8.26M)
Operating Margin-73.6%-122.3%-53.0%-25.9%-7.8%
Interest Income00000
Interest Expense27.83M1.1M3.19M1.63M3.42M
Other Income / Expenses(15.88M)5.31M(4.26M)7.74M(31.39M)
Income Before Tax(71.67M)(79.31M)(32.89M)(12.48M)(39.65M)
Pre-Tax Margin-94.5%-114.6%-60.9%-16.0%-37.5%
Income Tax Expense31K29K10K54K28K
Net Income(71.7M)(79.34M)(32.9M)(12.54M)(39.68M)
Net Margin-94.5%-114.6%-60.9%-16.1%-37.5%
EPS (Basic)(12.47)(9.97)(4.53)(0.83)(2.24)
EPS (Diluted)(12.47)(9.97)(4.53)(0.83)(2.24)
Weighted Avg Shares7.87M7.95M8.28M15.11M562.5M
Weighted Avg Shares (Diluted)7.87M7.95M8.28M15.11M562.5M

Owlet, Inc.

NYSE:OWLT

Intrinsic Alpha fair value

Locked

Current Price

$3.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.